Featured Articles

  1. Bioprocessing And Scaleup Of HEK293 Cells For AAV Production 5/9/2022

    MilliporeSigma has developed the VirusExpress®️ AAV Production Platform as a scalable upstream AAV production solution for viral gene therapies.

  2. Viral Clearance Considerations For Adeno-Associated Virus (AAV) Viral Vectors 4/11/2022

    There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here we address some of the questions with respect to viral clearance studies for AAV vectors.

  3. Lay The Proper Foundation For Upstream Success 4/7/2022

    When selecting a partner for development of upstream processes you need speed, quality and regulatory compliance – all appropriately balanced.

  4. A Platform Standard For Viral Vector Manufacturing And Commercialization 4/6/2022

    Learn more about platform technologies that are being developed and implemented to support large-scale production of viral vectors.

  5. Optimizing Feed Strategies: A Scalable Process 4/1/2022

    We present an optimized feeding strategy and demonstrate how a new, easy-to-hydrate, single-part, pH neutral feed can support optimal cell growth and high productivity of CHO cell lines.

  6. Explore Performances Of The EX-CELL® CD Insect Cell Medium 3/29/2022

    Because viral safety is essential in the manufacture of biopharmaceuticals, we developed a proven Sf9-rhabdovirus-negative insect cell line that improves the safety profile of our customers’ bioprocesses.

  7. Enabling Vaccine Production: Solving Challenges Together 3/29/2022

    This e-book contains a series of case studies highlighting our recent collaborations with organizations and thought leaders on the front lines of the battle against challenging pathogens and infectious diseases. 

  8. The Evolution Of AI: Benefits To Biopharma 3/23/2022

    Considering the complexity of bioprocessing and the industry’s inherent “data siloes,” this paper focuses on how companies can use the power of smart data to leverage AI and drive additional insights.

  9. Chemically Defined Cloning Medium For Quality, Regulatory Risk Mitigation 3/18/2022

    We review the performance and stability of a novel, chemically defined cloning medium that accelerates clone isolation, reduces the risk of variability in protein quality, and reduces impurities.

  10. Perspectives On Trends In Outsourcing The Development And Manufacturing Of Biologics 3/18/2022

    Read more on trends related to outsourcing and share what attributes of an outsourcing partner that are sought by developers and manufacturers of biopharmaceuticals.